Success Metrics

Active Trials

1(25%)

Phase Distribution

Ph phase_3

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

1(25.0%)

Phase 3Large-scale testing

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Other(1)

Detailed Status

Not yet recruiting2

Active, not recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 21 (25.0%)

Phase 33 (75.0%)

Trials by Status

not_yet_recruiting250%

active_not_recruiting125%

unknown125%

Recent Activity

1 active trials

Showing 4 of 4

not_yet_recruitingphase_2

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319

not_yet_recruitingphase_3

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

NCT07109531

active_not_recruitingphase_3

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

NCT05015608

unknownphase_3

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

NCT06110663

Clinical Trials (4)

Showing 4 of 4 trials

NCT07365319Phase 2

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Not Yet Recruiting

NCT07109531Phase 3

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Not Yet Recruiting

NCT05015608Phase 3

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Active Not Recruiting

NCT06110663Phase 3

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Unknown

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4